Moreover, 75% of the AML primary cells resistant to AKT inhibitors presented high IGF1R/IRS1 phosphorylation, and the combination of AKT inhibitors and the IGF1R inhibitor linsitinib potentiated PI3K/AKT/mTOR inhibition 85. The gene discussed is AKT1; the disease is acute myeloid leukemia.